NIH-funded research R01 grant

How different NRAS mutations affect cancer development

Official title: Molecular mechanisms of allele-specific NRAS signaling and tumorigenesis

Funded at Ohio State University · NIH-10980720 · Data updated 2026-11-12

This study is looking at how different changes in the NRAS gene affect cancer, especially in people with acute myeloid leukemia and melanoma, to help understand why some patients respond better to treatments than others.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionOhio State University
NIH-funded
Lab location1 site (Columbus, UNITED STATES)
Project startJuly 1, 2024
Project endJune 30, 2029
Funding year2024
Award (this year)$640,969
NIH project number1R01CA287193-01A1
Project IDNIH-10980720 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are patients diagnosed with acute myeloid leukemia or melanoma who have specific NRAS mutations.

Less likely to help

Patients without NRAS mutations or those with other types of cancer may not benefit from this research.

What this research studies

This research investigates the specific ways in which different mutations of the NRAS gene contribute to cancer, particularly focusing on acute myeloid leukemia and melanoma. By studying various NRAS mutations in mouse models, the researchers aim to understand how these mutations influence cancer progression and response to treatment. The approach involves examining the biochemical properties of NRAS mutants and their interactions with other proteins involved in cell signaling. This could lead to insights into why certain patients respond differently to therapies based on their specific NRAS mutations.

Why it matters

Potential benefit: If successful, this research could lead to more personalized treatment strategies for patients with acute myeloid leukemia and melanoma based on their specific NRAS mutations.

How similar studies have gone: Previous research has shown that understanding specific mutations in cancer genes can lead to significant advancements in treatment, suggesting that this approach has the potential for success.

Where this research is happening

  • Ohio State University
    Columbus, United States
    Active

Researchers

  • Principal investigator: Burd, Christin E — Ohio State University
  • Study coordinator: Burd, Christin E

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.